Commenting on the quarter, CEO
"More than ever, the world is looking for safe and effective solutions to gut health. Anatara's progress to-date in developing evidence-based solutions for the sufferers of gut symptoms, including both irritable and inflammatory bowel syndromes, is now focused on the commencement of our human trials. The human clinical trials are the key next step to moving closer to commercialisation and entering the US$8+ billion gastrointestinal supplements and over-the-counter digestive remedies market."
Irritable Bowel Syndrome (IBS) Trial Recruitment imminent
Anatara has strong pre-clinical data to support GaRP use in IBS, the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care. Anatara received
The Company has prepared its trial recruitment website which will be launched very soon following Covid related manufacturing delays. GaRP has been manufactured and shipped and the placebo has been coated and is presently being packaged. Recruitment for both GaRP and 3FDC clinical trials are anticipated to commence during the next quarter.
Ethics approval to start Psychological Functioning Trial in adults
Anatara announced in April that it had received
3FDC is one of the components of Anatara's GaRP dietary supplement with a method of action in the large intestine. One aspect is to assist the homeostasis of the microbiome which is considered important for the "gut-brain axis" balance. The 3FDC components have been selected to explore their effects on depression, anxiety and stress symptoms in otherwise healthy individuals.
The
Australian patent grant for Detach(R)
In April Anatara announced the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance".
Anatara's animal heath product, registered in
The patent claims cover an oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The patent is fully owned by Anatara and will expire on
The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach(R).
BONIFF piglet challenge study
To address piglet scour, which is estimated to cost the Australian pig industry more than
Subject to successful results, discussions will commence with pig producers and animal feed/nutrition companies.
Summary of Q4 FY21 cashflows
The Company's cash plus term deposits at the end of the quarter stood at
Net cash outflow during the quarter was
Aggregate payments to related parties and their associates during the quarter was
Near term operational milestones
Over the next 6-12 months, the Company is aiming to:
- Sign a commercial agreement for one or more of Anatara's health products
- Commence recruitment for the clinical study with GaRP in IBS patients;
- Commence recruitment of the clinical study with 3FDC in adult participants with moderate anxiety, stress or depression
"With an active program in place over the next 6 to 12 months, including the pursuit of partnership agreements, we are well placed to advance the commercialisation of our current health products", concluded Mr Lydeamore.
To view the cashflow report, please visit:
https://abnnewswire.net/lnk/0846W0GW
About
Contact:
Steven Lydeamore
CEO,
+61 (0) 438 027 172
slydeamore@anatara.com
Dr.
Chairman,
+61 (0) 411 712 579
dbrookes@anatara.com
Copyright (C) 2021 ABN Newswire. All rights reserved., source